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Background: The association between the Val158Met polymorphism in the catechol-O-methyltransferase (COMT)
gene and lung cancer risk remains controversial and inconclusive. Therefore, the meta-analysis was performed to
provide a quality reevaluation of the association between the COMT Val158Met polymorphism and the risk of lung
cancer.
Methods: Two major public databases (Pubmed and Embase) and several Chinese databases were searched for
eligible studies. Pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated to estimate the strength
of the association.
Results: Five publications, including six individual studies with a total of 4,043 subjects (1,796 cases and 2,247
controls) regarding the association of COMT Val158Met polymorphism with lung cancer susceptibility were included
in this meta-analysis. Overall, pooled analysis indicated that there was no significant association between COMT
Val158Met polymorphism and lung cancer susceptibility under all genetic models. Likewise, no association was
observed in the stratified analysis by ethnicity and control source, either. However, Val158Met polymorphism was
shown to increase lung cancer risk among women (AG vs. GG, OR = 1.190, 95% CI = 1.001–1.422, p = 0.049).
Conclusion: These findings suggested that the COMT l58Val/Met polymorphism confer genetic susceptibility to
lung cancer among women. However, no evidence was found for the association with lung cancer risk in ethnicity
and smoking status.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_192
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Lung cancer is the most frequently diagnosed cancer
and is also considered as one of the most commonly
lethal malignancies worldwide [1]. Despite the high mor-
bidity and mortality of lung cancer, its etiology remains
largely unknown. There are multiple factors and multi-
step processes contributing to lung cancer, among which
environmental exposures, such as arsenic, asbestos, radon,
and polycyclic aromatic hydrocarbons, specially tobacco
smoking, are the major risk factor [2]. However, only a
small proportion individual exposed to these carcinogens
eventually develop lung cancer in the lifetime. Besides* Correspondence: chen535@126.com
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unless otherwise stated.environmental risk, it has been believed that genetic fac-
tors also play a role in the development of lung cancer.
The catechol-O-methyl transferase (COMT) gene is
located on the chromosome 22q11.2. The Val158Met
(rs4680, G > A) single nucleotide polymorphism (SNP)
in COMT gene have been identified in a protein coding
region [3], which leads to a common substitution of
methionine (Met) for valine (Val) at codon 158, This SNP
has been reported to affect the activity of the COMT
enzyme. For instance, individuals with the variant Met/
Met genotype have a 3- to 4- fold lower COMT enzyme
activity than those with wild-type Val/Val genotype [4].
COMT enzyme is involved in methylation of catechol
estrogens, especially catechol estrogens formed from the
2- and 4-hydroxylations of estradiol. Reduced the activity
of this enzyme may lead to increasing the accumulation ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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age through participating in redox cycling processes or
quinones metabolism [4-7]. The DNA adducts can gener-
ate apurinic sites that may lead to cancer-initiating muta-
tions [8] cause cellular transformation [9,10], and thereby
initiate cancer development.
Up to date, a number of molecular epidemiologic case–
control studies have shown the potential role of COMT
Val158Met polymorphism in the risk of lung cancer. How-
ever, the results remain inconclusive and controversial.
For example, Zhang et al. [7] had shown that COMT
Val158Met was significantly associated with a reduced risk
of NSCLC, whereas Lim et al. [11] had suggested that the
variant A allele of COMT Val158Met polymorphism was
positively associated with lung cancer in never-smokers.
So far, no meta-analysis had been conducted to investigate
the association between COMT Val158Met polymorphism
and Lung cancer. With this in mind, we performed
this meta-analysis with large samples to reevaluate this
association.
Methods
Searching strategy and selection criteria
A comprehensive literature search was conducted in two
comprehensive literature search engine (Pubmed, Embase),
and several Chinese database, such as, Chinese Biomedical
database, China National Knowledge Infrastructure (CNKI)
and Wan fang (WF) Database until October 20, 2013.
The search terms were “catechol-O-methyltransferase or
COMT”, “Val158Met or rs4680 or G472A”, “polymorph-
ism or variant or variation”, and “lung cancer or lung
carcinoma”. Additionally, we identified extra studies by
manually searching of the references lists of retrieved
studies. All eligible studies included in our meta-analysis
were conducted on human subjects, and published in
either English or Chinese. If several studies overlapped
with each, we only selected the one with the largest sam-
ple size or the one published most recently. The included
studies have to meet the following criteria: (1) full-text
studies were included, (2) designed as nested case–control,
case–control, or cohort study, (3) estimated the association
between COMT Val158Met variant and lung cancer, (4)
odds ratio (OR) and the corresponding 95% confidence
interval (CI) were provided, and (5) provided the sufficient
genotypic or allelic information to estimate.
Data extraction
Information was extracted carefully from all eligible
studies independently by two investigators (X. Tan and
MW. Chen). All disagreements were resolved by fully
discussing between two investigators until a consensus
was reached. The following data were collected from
each study: first author’s surname, publication date, coun-
try, ethnicity, source of control, genotyping method, andgenotype counts (GG, GA, and AA) of cases and controls
(Table 1).Quality assessment
The Newcastle-Ottawa Scale (NOS) was used to assess
the methodological quality of studies included in our
meta-analysis. The NOS consists of eight items that are
further classified into three categories: selection, com-
parability, and outcome. A star system was created to
Semi-quantitatively weigh up the study quality. The
comparability group was granted two stars whereas other
each items awarded a maximum of one star in highest
quality studies. The range of 1–9 stars in the NOS was
adopted for estimation, with more stars indicating a
higher quality study [12]. Since standard criteria had not
been established, we considered study that was rated
seven or more stars as a high quality study in the current
meta-analysis.Statistical analysis
The strength of association between COMT Val158Met
(G > A) polymorphism and lung cancer risk was assessed
by the pooled ORs with 95% CIs. The pooled estimates
were performed under several genetic models, including
allele comparison model (A vs. G), homozygote compari-
son (AA vs. GG), heterozygote comparison (AG vs. GG),
dominant model (AA/AG vs. GG), and recessive model
(AA vs. AG/GG).
Chi-square-based Q test and p-value were used to test
the statistical heterogeneity between studies. A P >0.10
and I2 < 25% for the Q test indicated that no heterogeneity
existed among studies. And 25% < I2 < 50% indicated that
there was moderate heterogeneity. If there was no hetero-
geneity, the fixed-effects model was adopted in Mantel–
Haenszel method; if I2 > 50% or p-value < 0.1, the random-
effects model was performed using the DerSimonian and
Laird method if I2 > 50% or p-value < 0.1 [13].
Hardy–Weinberg equilibrium (HWE) was checked in
controls by the chi-square test, and a p-value less than
0.05 represented significant deviation from HWE [14].
An asymmetric plot demonstrated a potential publica-
tion bias. The Begg’s and Egger’s test were carried out to
detect potential publication bias, with a P < 0.05 indi-
cating that there was a significant publication bias in the
study [15].
The false-positive report probability (FPRP) [16,17]
was carried out to validate the significant results. A
FPRP value of 0.2 threshold and a prior probability of
0.01 were preset to detect an OR of 1.50 (for risk effects)
or 0.67 (for protective effects) for an association between
the studied SNP and lung cancer risk. Only significant
associations with a FPRP value less than 0.2 were con-
sidered as noteworthy.
Table 1 Studies and data included in this meta-analysis
Investigator Year Race Country Case Control HWEa Control source Methods NOSb score
AA AG GG AA AG GG pa
Zhang et al. [7] 2013 Asian China 11 69 120 19 78 103 0.454 HBc Sequence 8
Lim et al. [11] 2012 Asian Singapore 39 220 284 63 353 549 0.539 HB PCRe 7
Cote et al. [18] 2009 Caucasian USA 102 205 78 114 197 92 0.696 PBd PCR 8
Cote et al. [18] 2009 Black USA 10 46 56 14 47 59 0.332 PB TaqMan 8
Zienolddiny et al. [20] 2008 Caucasian Norway 32 62 163 8 60 202 0.182 PB Sequence 8
Gemignani et al. [19] 2007 Caucasian European 59 144 83 75 146 81 0.569 HB PCR 7
pa for Hardy–Weinberg equilibrium in control group; bfor Newcastle-Ottawa Scale. cfor hospital-based; dfor population-based; efor polymerase chain reaction.
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ethnic subgroup (Asian and Caucasian), control source
(Population-based and Hospital-based) and smoking
status (Never-smokers and Ever-smokers). All statistic
except for FPRP analysis, were performed by using the
Stata software version11.1 (Stata Corporation. USA).
And FPRP was conducted by using SAS software (version
9.1; SAS Institute, Cary, NC). All P values were two-sided,
and a P value less than 0.05 were considered statistically
significant.
Results
Characteristics of relevant studies
According to the previously described search strategy
and inclusion criteria, the literature selection process
was shown in Figure 1. Among all the eligible studies,Figure 1 The publication selection process of this meta-analysis.study by Cote et al. [18] reported the genotype frequency
of both Africans and Caucasians; thus the data were
collected separately based on ethnicities and considered
as two studies. Therefore, five publications [7,11,18-20],
consisting of six individual studies with a total of 4,043
subjects (1,796 cases, 2,247 controls) regarding asso-
ciation of COMT Val158Met polymorphism with lung
cancer risk were included in this meta-analysis. The
study characteristics are summarized in Table 1. In term
of the ethnicity, there were 2 studies [7,11] conducted
among Asians, 3 studies [18-20] among Caucasians, and
the remaining 1studies [18] among Africans. Regarding
the source of control, there were 3 population-based
studies and 3 hospital-based studies. Smoking is a major
factor contributing to the development of lung cancer.
Only 3 studies [7,11,20] provided genotype counts of
Tan and Chen Diagnostic Pathology 2014, 9:192 Page 4 of 8
http://www.diagnosticpathology.org/content/9/1/192cases and controls separately by the smoking status and
separated the raw data of genotype was separated for
further analysis. In addition, 2 publications [11,18], in-
cluding 3 individual studies performed among women
were included in the meta-analysis.
Meta-analysis results
The meta-analysis results on the association between
COMT Val158Met polymorphism and the risk of lung
cancer are shown in Table 2. When between-study
heterogeneity was significant, the random-effects model
was performed in our analysis; otherwise, fixed-effects
model was adopted used. By pooling eligible studies
together, the results derived from random-effect models
indicated that variant allele (A) of COMT Val158Met was
not associated with lung cancer (A vs. G, OR = 1.052, 95%
CI = 0.837–1.322, p = 0.664). Similarly, no significant asso-
ciations were observed under all other genetic models
(homogenous: AA vs. GG, OR = 1.088,95% CI = 0.677–
1.749, p = 0.729; heterogeneous: AG vs. GG, OR = 1.107,
95% CI = 0.962–1.275, p = 0.157; dominant: AA/AG vs.
GG, OR = 1.085, 95% CI = 0.867–1.357, p = 0.477; reces-
sive: AA vs. AG/GG, OR = 1.037, 95% CI = 0.686–1.568,
p = 0.863) (Table 2, Figure 2).
Moreover, in the stratified analysis by ethnicity, there
was no significant association between COMT Val158Met
polymorphism and lung cancer risk among Caucasians
and Asians (Table 2). Further stratified analysis by source
of controls or smoking status observed, no significant
association (Table 2). However, we found a borderline
significant association between risk Vall58Met poly-
morphism and the risk of lung cancer among women
under the heterogeneous model (AG vs. GG, OR = 1.190,
95% CI = 1.001–1.422, p = 0.049) (Figure 3).
FPRP analysis indicated that, for a prior probability of
0.1, assuming that the OR for specific genotype was 0.67/
1.50 (protection/risk), Val/Met carriers for women were
not increased lung cancer risk at the prior probability level
of 0.1or 0.01 (power = 0.999, f0.1 = 0.306, f0.01 = 0.829).
However, these finding need further validation with larger
sample sizes, because of some possible bias that resulted
from small sample size in subgroups.
Test for heterogeneity, sensitive analysis, and test for
publication bias
Significant heterogeneity was observed in the overall
pooled analysis, whereas, the degree of heterogeneity was
decrease in the stratified analysis. In order to assess the
stability of the present meta-analysis, sensitivity analysis
was performed by deleting one study at each time (data
not shown) and recalculating ORs and 95% CIs. Overall,
the pooled estimates were not materially altered upon the
removal of any of single study, suggesting that the stability
of the results.Begg’s funnel plot and Egger’s test were conducted to
estimate the publication bias. The shape of the funnel
plot revealed no evidence of obvious asymmetry in this
meta-analysis (Figure 4). Likewise, Begg’s and Egger’s test
indicated no evidence of publication bias, either (AA ver-
sus GG, Begg’s test, P = 0.851, Egger’s test, p = 0.810; AG
versus GG, Begg’s test, P = 0.188, Egger’s test, p = 0.345;
dominant model, Begg’s test, P = 0.348, Egger’s test, p =
0.529; recessive model, Begg’s test, P = 0.851, Egger’s test,
p = 0.599).
Discussion
Lung cancer is the leading cause of cancer-related mor-
tality worldwide. Lung carcinogenesis is a complicated
long multi stage process, involving the interplay of can-
cer susceptibility genes and specific environmental expo-
sures [21]. For example, a personal history of cigarette
smoking probably is the most important contributor to
the imitation and development of tobacco-related lung
cancer. Apart from smoke exposure, genome-wide associ-
ation studies (GWAS) has provided a strong evidence that
tobacco-dependent lung cancer patients had a susceptibil-
ity region in chromosome 15q25.1, including some genes
(CHRNB4, CHRNA3, and CHRNA5) that encode for nic-
otinic acetylcholine receptors [22]. These results suggest
that genetic and environmental risk factors may collabora-
tively contribute lung cancer carcinogenesis.
Numerous studies have adopted a candidate gene ap-
proach to explore the effects of genetic variations on the
genetic susceptibility to lung cancer. A large proportion of
relevant studies has been focused on SNPs in the genes
coding for enzymes involved in tobacco carcinogen
metabolism (e.g. CYP1A1 and NQO1) and genes involved
in DNA repair (e.g. XRCC1) [23,24]. Moreover, so many
meta-analysis had investigated the association between the
gene polymorphisms and the risk of lung cancer. The
meta-analysis of Tan et al. [25] had reported a correlation
between (ERCC2) Lys751Gln polymorphism and an
increased risk of lung cancer based on 23,370 subjects.
Wang et al. [26] performed a meta-analysis showed that
there was no association between IL-6 rs1800796 poly-
morphism and lung cancer, etc. Therefore, Meta-analysis
can provide a quantitative summary of the available data
that will be stronger evidence for identifying the associ-
ation between gene variations and cancer risk.
COMT polymorphism has also gained more and more
attentions in this field. In addition, COMT is a rate-
limiting enzyme that played a role in the detoxification
of catechol estrogens. Reduced activity of this enzyme
might cause the accumulation of catechol estrogens,
which may sequentially lead to oxidative DNA damage
[18,27]. Estrogen receptor β is expressed in lung tissue,
and estrogen receptor antagonists could significantly inhibit
growth in non-small-cell lung cancer cell lines [28,29].
Table 2 Stratified analyses of the COMT gene polymorphism and lung cancer risk
Variable n AA vs. GG AG vs. GG AA/AG vs. GG AA vs. AG/GG
OR (95% CI) pa pb OR (95% CI) pa pb OR (95% CI) pa pb OR (95% CI) pa pb
Total 6 1.088 (0.677–1.749) 0.729 0.001 1.107 (0.962–1.275) 0.157 0.407 1.085 (0.867–1.357) 0.477 0.03 1.037 (0.686–1.568) 0.863 0.002
Ethnicity
Asian 2 0.823 (0.351–1.930) 0.654 0.054 0.991 (0.634–1.549) 0.968 0.055 0.949 (0.566–1.592) 0.842 0.02 0.848 (0.438–1.642) 0.626 0.121
Caucasian 3 1.480 (0.627–3.491) 0.371 0.001 0.993 (0.797–1.238) 0.227 0.544 1.210 (0.845–1.732) 0.299 0.049 1.350 (0.642–2.839) 0.429 0.001
Control source
Hospital-based 3 0.836 (0.531–1.315) 0.438 0.112 1.061 (0.892–1.262) 0.505 0.136 0.946 (0.687–1.304) 0.735 0.047 0.854 (0.612–1.192) 0.354 0.236
Population-based 3 1.560 (0.562–4.336) 0.393 0.001 1.204 (0.945–1.534) 0.134 0.816 1.277 (0.929–1.755) 0.132 0.153 1.434 (0.519–3.966) 0.487 0.001
Smoking status
Never-smokers 2 0.846 (0.330–2.169) 0.728 0.043 1.064 (0.574–1.972) 0.844 0.012 1.016 (0.518–1.992) 0.963 0.004 0.842 (0.427–1.658) 0.618 0.13
Ever-smokers 2 2.326 (0.503–10.756) 0.28 0.014 0.994 (0.590–1.677) 0.983 0.096 1.174 (0.548–2.517) 0.680 0.010 2.394 (0.619–9.262) 0.206 0.028

















Figure 2 Forest plots of COMT Val158Met polymorphism and lung cancer in the overall analysis using the fixed-effect dominant model
(AG vs. GG).
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and estrone to catechol estrogens that plays a key role in
carcinogenesis [30].
Several epidemiologic studies have reported the role of
COMT Val158Met polymorphism in the risk of lung
cancer. Zienolddiny et al. [20] suggested that the exonic
SNP (Val158Met) of the COMT gene was associated
with an increased risk of lung cancer. Intriguingly, Zhang
et al. [7] reported an opposite results in his research.
Therefore, the previous results were conflicting and
inconclusive. Although only limited studies were included,
our meta-analysis provided a new evidence of the null
association between COMT Val158Met polymorphism andFigure 3 Forest plots of COMT Val158Met polymorphism and lung caoverall lung cancer risk. To the best of our knowledge, this
is the first meta-analysis that has evaluated the relationship
between the COMT Vall58Met polymorphism and the risk
of lung cancer.
Furthermore, COMT Vall58Met polymorphism appeared
to have no influence on the risk of lung cancer either, when
studies were stratified by ethnicity, source of controls and
smoking status. There might be due to different genetic
backgrounds or some other potentially suspected factors,
which influenced our research.
The stratified analysis by sex observed a borderline
significant association of COMT Val158Met polymorph-
ism among women. To avoid false positive result fromncer among women using the fixed-effect model (AG vs. GG).
Figure 4 Begg’s funnel plot of the meta-analysis of lung cancer risk and COMT Val158Met polymorphism (AA + AG vs. GG). Begg's
funnel plot with pseudo 95% confidence limits.
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for these significant findings. Nevertheless, Val/Met carriers
were not increased lung cancer risk at the prior probability
level of 0.1or 0.01. There are several possible explanations
for these findings. Some findings in the stratified analysis
may be discovered by chance because of multiple compari-
sons and the limited sample size in the subgroups. Given
only a few studies were included in this meta-analysis, it
was hard to draw firm conclusions from this current
analysis. Particularly, the borderline significant association
for women was just based on 2 studies. Therefore, these
findings should be interpreted with caution.
We used the methods of the Newcastle-Ottawa Scale
(NOS) to assess the quality of the studies included in
our meta-analysis. As a result, three studies [7,18,20]
were rewarded eight stars, while two studies [11,19] were
rewarded seven stars according to the NOS assessment
system. Zhang et al. [7] and Lim et al. [11] had identified
the association of COMT Val158Met polymorphism with
the risk of lung cancer in Chinese non-smokers. The limi-
tations of study by Zhang et al. [7] was that the sample
size was small, and they did not analyze the effects of
second-hand smoke and exposure to cooking smoke on
the risk of NSCLC. The strengths of study by Lim et al.
[11] included homogeneity with regard to gender and
ethnicity and the large number of never-smokers. How-
ever, this study might be subjected to biases that exist in
the hospital-based case–control studies. The individual
data about environmental factors in the study by the Cote
et al. [18] were relatively were detailed, including infor-
mation on past medical and reproductive histories, occu-
pational exposures, BMI, etc. Therefore, this study was
able to explore the gene–gene and gene–environment
interactions that influence an individual lung cancer risk.
Nevertheless, the majority of the subjects in the studywere lung adenocarcinomas. Thus, the findings might not
be representative of lung cancer. Zienolddiny et al. [20]
and Gemignani et al. [19] performed the genotyping of
more than one hundred polymorphisms in genes in-
volved in carcinogen and xenobiotic metabolism. How-
ever,the sample sizes of both studies were moderate.
Therefore, there probably existed potential confounding
false positives.
Although we took considerable efforts to collect all
available data to investigate the association of COMT
Vall58Met polymorphism and its correlation with lung
cancer risk, there were also some limitations to be ad-
dressed. Firstly, there were only a few studies investigating
relationship between COMT polymorphisms and lung
cancer risk, therefore, the sample size of our meta-analysis
was relatively small. Moreover, this meta-analysis might
be also subjected from population stratification, a system-
atic difference in allele frequencies between subpopula-
tions. In some cases, positive finding of an association
study could result from population stratification, instead
of a true association between studies SNP and disease.
Secondly, our meta-analysis was based on unadjusted esti-
mates, while a more precise analysis should be performed
if individual data such as age, smoking status, lifestyle and
environmental factors were available. These factors may
be sources of the heterogeneity. Thirdly, only five studies
were retrieved from Pubmed, Embase, China National
Knowledge Infrastructure, and Medline data base. And
unpublished studies and conference abstracts were exclu-
ded from the current study. Although Begg’s funnel plot,
Begg’s test, and Egger’s test were conducted to estimate
the publication bias. Lack of publication bias in this study
might be due to the fact that Egger’s test was not very
powerful with only a few studies in the meta-analyses, the
results must be considered cautious. In spite of these
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single study.
Conclusions
In conclusion, no significant association was found be-
tween COMT Vall58Met polymorphism and lung cancer
risk in the overall analysis. However, a borderline sig-
nificant association indicated that COMT Vall58Met
polymorphism might increase lung cancer susceptibility.
Finally, high-quality case–control studies with large sam-
ple sizes will be required to confirm these findings.
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